Hutchmed (China) Ltd is not a strong buy at the moment given the lack of significant positive catalysts, neutral trading sentiment, and technical indicators showing no clear upward momentum. For a beginner investor with a long-term strategy, it may be better to hold off on buying until stronger signals or catalysts emerge.

Technical Analysis

The MACD is negative and expanding downward (-0.0263), RSI is at 35.198 (neutral zone), and moving averages are converging, indicating no clear trend. The stock is trading below the pivot level of 14.9, with key support at 14.487 and resistance at 15.312.

Options Data

Bearish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Technical Summary

Sell

Buy

Positive Catalysts

BofA maintains a Buy rating with a revised price target of $22, citing positive data catalysts and improving access to capital in the biotech sector.

Neutral/Negative Catalysts

The stock has seen a regular market change of -2.90%, and there are no significant insider or hedge fund trading trends. Additionally, the MACD and RSI do not indicate bullish momentum, and there is no recent news or congress trading data to support a buy decision.

Financial Performance

No financial performance data available for analysis.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

BofA lowered the price target from $25 to $22 but maintains a Buy rating, reflecting cautious optimism in the biotech sector.

1 Analyst Rating

Wall Street analysts forecast HCM stock price to rise

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 14.330

Low

Averages

High

Current: 14.330

Low

Averages

High

BofA

Buy

downgrade

$25 -> $22

AI Analysis

2026-01-06

Reason

BofA

Price Target

$25 -> $22

AI Analysis

2026-01-06

downgrade

Buy

Reason

BofA lowered the firm's price target on Hutchmed to $22 from $25 and keeps a Buy rating on the shares. The firm is updating its price targets for U.S Biopharmaceuticals under its coverage, the analyst tells investors. Over the past few months, several key items "have fallen into place," including positive data catalysts being rewarded; large-cap biopharma spending cash on M&A and in-licensing; growing backlog of companies on the private side; improving access to capital; and limited impact from drug price regulation, BofA says. The firm believes biotech is back, but the biggest concern is whether this will last.

Morgan Stanley

Equal Weight -> Underweight

downgrade

$18

2025-09-22

Reason

Morgan Stanley

Price Target

$18

2025-09-22

downgrade

Equal Weight -> Underweight

Reason

Morgan Stanley downgraded Hutchmed to Underweight from Equal Weight with a price target of $13.75, down from $18. The company reduced its commercial guidance amid a restructuring and its \"lackluster\" near-term growth could drive a valuation de-rating, the analyst tells investors in a research note. The firm says Hutchmed's approved assets could be entering a period of declining product life cycles and patent expirations.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for HCM

Unlock Now

HCM Should I Buy

HCM Should I Buy

Should You Buy HUTCHMED (China) Ltd (HCM) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch